相关实验视频

Updated: Jun 21, 2025

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

在先前治疗的,局部先进的不可切除/转移的微卫星不稳定性高/不匹配修复缺陷的固体瘤中使用tislelizumab

Jian Li¹, Ye Xu², Aimin Zang³

¹State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.

Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

|July 11, 2024

概括

抗PD-1抗体的tislelizumab显著改善了先前接受MSI-H/dMMR固体瘤治疗的患者的客观反应率. 免疫疗法耐受性很好,在这个难以治疗的人群中显示出有希望的结果.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
固体瘤是一种固体瘤.

背景情况:

微卫星不稳定性高 (MSI-H) /不匹配修复缺陷 (dMMR) 固体瘤代表了一个独特的分子亚型,对治疗的反应各不相同.
蒂斯莱利祖马布是一种抗编程细胞死亡蛋白1 (PD-1) 抗体,研究其治疗潜力.

研究的目的:

评估tislelizumab作为组织无定性单疗法在先前治疗,局部先进的不可切除或转移的MSI-H/dMMR固体瘤的成年患者.
评估客观反应率 (ORR) 作为主要终点,以及反应持续时间 (DoR) 和无进展生存期 (PFS).

主要方法:

一项开放的II期研究 (RATIONALE-209) 招募了患有MSI-H/dMMR固体瘤的患者.
患者接受了tislelizumab200毫克静脉注射每3周一次.
结果被一个独立的审查委员会评估,使用响应评估标准在固体瘤v1.1.1.

主要成果:

整体ORR为46.7%,明显超过10%的历史对照 (P<0.0001).
在各种瘤亚组中观察到反应,包括结直肠,胃和胃食道结癌.
长期随访时没有达到中位数的DoR,PFS和整体存活期;tislelizumab耐受性很好,可控不良事件.

结论:

蒂斯莱利祖马布在先前接受MSI-H/dMMR固体瘤治疗的患者中显著改善了ORR.
抗PD-1抗体通常耐受良好,支持其作为这种患者群体治疗选择的潜力.

关键词:

生物标志物生物标志物修复DNA不匹配的修复免疫检查点抑制剂免疫检查点抑制剂微卫星的不稳定性二期临床试验的临床试验.编程细胞死亡1受体受体

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma

An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma

Published on: November 15, 2024

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.